Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

REMS Class-Action Lawsuit Against Celgene Is First By Patients

Jun 20 2017

• By Michael Cipriano

GoldKeyInPuzzle_1200x675

Related Content

The Impact of REMS on Generic Drug Approvals and Drug Competition

May 03 2012

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill

Apr 30 2017

FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene

Jun 20 2014

US Patent Battles May Resume Next Congress; Reps Press For IPR Reform

Dec 13 2016

Generic Companies Gain Little From FDA Decision On Access To REMS Drugs

Aug 13 2013

Natco Doubles Down On US With Ambitious ANDA Plan

Sep 23 2016

REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing

Mar 03 2017

FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution

Jun 08 2017

Related Companies

Bristol Myers Squibb Company

Viatris Inc.

Lannett Company, Inc.

Dr. Reddy's Laboratories Ltd.

Actelion Pharmaceuticals Ltd.

Apotex Inc.

Hikma Pharmaceuticals plc

Allergan plc

Accord Healthcare Ltd.

Intas Pharmaceuticals Ltd.

Acorda Therapeutics, Inc.

Barr Pharmaceuticals

Additional Topics

United States Drug Safety Generic Drugs Intellectual Property Legal Issues Policy Cancer BioPharmaceutical

More from Drug Safety

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window